The U.S. is having its worst year for measles spread in more than three decades, with a total of 1,288 cases nationally and ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

Novo Nordisk seeks EMA approval for 7.2 mg Wegovy dose after trials show 21% weight loss in people with obesity and type 2 diabetes.

Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the ...

Zepbound's results were relatively unchanged year over year, though the number of U.S. patients starting on the medication in 2023 was limited since it did not launch until November of that year.

LOS ANGELES, June 25 (Reuters) - Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year later, according to an analysis of U.S ...

Novo Nordisk has launched its anti-obesity drug Wegovy in India, aimed at long-term weight management and reducing cardiovascular risk. The company targets large-scale distribution, aiming to become a ...

Novo Nordisk confirmed on Monday it would cease its agreement with U.S. telehealth firm Hims & Hers Health regarding its Wegovy weight-loss drug, prompting a 31% dip in Hims shares during morning ...

Novo Nordisk has ended its partnership with Hims & Hers, citing concerns over the telehealth company’s promotion and sale of the drugmaker’s compounded versions of Wegovy. The drugmaker ...

Pharmaceutical giant Eli Lilly that new preliminary research indicates its medication Zepbound helps patients lose more weight in a shorter time frame compared to Novo Nordisk's Wegovy. According ...